AOA Dx, a biotech startup based in the United States, has successfully raised $17M to accelerate the development of its liquid biopsy test for ovarian cancer. This round was led by Good Growth Capital with participation from industry leading investors including RH Capital, Y Combinator, Astia, Adaptive Capital Partners, Gore Range Capital, LongeVC, The Helm, VU Venture Partners, FemHealth Ventures, CANCER FUND along with strategic diagnostic investors, including Labcorp Venture Fund. AOA Dx’s innovative approach revolves around…
